2025年2月27日 · ACS are typically caused by the disruption ... The use of evidence-based clinical decision pathways (CDPs) has been shown to improve outcomes and direct appropriate use of resources. 13 CDPs reduce unnecessary testing in 21% to 43% of patients while maintaining a high negative predictive value for major adverse cardiovascular events (MACE). 16 ...

The Pathway for Acute Coronary Syndrome Assessment (PACSA) is a set of documents that outline how to assess and manage patients with suspected acute coronary syndrome (ACS). PACSA has been designed to standardise practice across all health services operating in NSW, including in rural, regional and metropolitan areas.

2023年6月27日 · Learn about acute coronary syndromes algorithm. Understand protocols for managing patients with ACS.

2020年11月18日 · Acute coronary syndromes are a possible sign of acute myocardial injury in patients with COVID-19. See recommendations on acute myocardial injury in our rapid guideline on managing COVID-19. Last reviewed: 19 December 2024.

2023年8月25日 · This guideline provides a comprehensive overview of the management of patients presenting with Acute coronary syndrome (ACS) from the point of diagnosis and risk stratification at initial presentation, through to long-term management after the initial hospitalisation period.

Low-Intermediate Risk ACS Pathway • Low-Risk ACS Order Set (#7035) • Repeat hs-TnT once 8 hours from first • Attending cardiologist to consider further diagnostic testing Patient develops 1 or more? •Clinical high-risk features •Dynamic EKG changes consistent with ischemia • HS-cTnT ≥ 100ng/L or ≥ 12ng/L increase

Presentation with clinical features consistent with suspected Non-ST-Elevation ACS (NSTEACS)

2025年2月28日 · Recommendations reflect the best evidence to support ACS treatment and management, including updated pharmacologic and procedural care. Dual antiplatelet therapy (DAPT), comprising aspirin plus a P2Y12 inhibitor, is already recommended for people with ACS. While it reduces the risk of recurrent MI, it can increase bleeding risk in some patients.

This pathway is for patients diagnosed with any one of the following: ST-segment Elevation Myocardial Infarction (STEMI) or High Risk Non-STEACS i.e. Non-STEMI (NSTEMI) or Unstable Angina (UA) Pathway commenced

Acute Coronary Syndrome (ACS) Guidelines Unstable angina, ST Elevation Myocardial Infarction (STEMI), Non ST Elevation Myocardial Infarction/Acute Coronary Syndrome (NSTEMI/NSTE-ACS) Printable version of this page